Poor Outcomes for Prostate Ca Pts With CAU

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 7
Volume 16
Issue 7

Prostate cancer patients who showed central abdominal uptake (CAU) on imaging with capromab pendetide (ProstaScint) had prostate-cancer-specific death rates 10 times higher than those without CAU

ANAHEIM, California—Prostate cancer patients who showed central abdominal uptake (CAU) on imaging with capromab pendetide (ProstaScint) had prostate-cancer-specific death rates 10 times higher than those without CAU, Michael J. Manyak, MD, and colleagues reported at the 2007 American Urological Association meeting (abstract 1018). The study shows the value of capromab pendetide in predicting prognosis in prostate cancer, said Dr. Manyak, vice president of medical affairs at Cytogen Corporation, manufacturer of ProstaScint, a monoclonal antibody/indium-111 agent that targets prostate-specific membrane antigen.

The investigators, led by Michael K. Haseman, MD, of Sutter Institute for Medical Research, Sacramento, reviewed records of 341 men with prostate cancer who underwent imaging with capromab pendetide between 1994 and 1999. Median follow-up was 4.1 years. CAU was found in 69 patients (20%). At a median follow-up of 4.1 years, 5 of these patients (7.2%) had died of prostate cancer, compared with 2 (0.7%) of the 272 CAU-negative patients (P = .005).

The tenfold increase in prostate-cancer-specific death rates was independent of the use or timing of intervention with hormone therapy, Dr. Manyak said. "These outcomes data confirm that high signal intensity in the abdomen is a negative prognostic sign," he concluded.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content